risks with glp 1 The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Medical professionals share risks of
Description
Does it work
The compounded GLP-1 era is ending
some head-to-head data suggest slightly higher GI events with Tirzepatide , but discontinuation rates remain modest with slow escalation
Future research should consider age-stratified data to better elucidate potential differential risks
I told them its not doing anything
